OTCMCHHE
Market cap18mUSD
Dec 12, Last price
0.28USD
Name
China Health Industries Holdings Inc
Chart & Performance
Profile
China Health Industries Holdings, Inc., through its subsidiaries, manufactures and sells health products. It offers hemp derivative products, such as hemp oil, hemp protein powder, hemp polypeptides, collagen peptides, hemp essence repair lotions, hemp revitalizing essence products, hemp anti-aging brightening eye creams, and hemp frozen age nourishing creams. The company also provides health supplements, including Sailuozhi soft capsule, which is made from frog oil, soybean isoflavone, procyanidine, and vitamin E for freckle removal and skin moisture supplements under the QunLe brand; and propolis and black ant capsule that is made from propolis, black ant, acanthopanax, and astragalus root under the Kindlink brand. In addition, it offers health products for acne removal, relieving eyestrain, enhancing bone density, enhancing memory, enhancing nutritional anemia and chloasma, relaxing bowels and promoting the discharge of lead, enhancing immunity and relieving physical fatigue, and dispelling chloasma, as well as iron and multivitamin, and mineral supplements. Further, the company manufactures and sells various types of medical drugs. It primarily sells its products through sales agents. China Health Industries Holdings, Inc. is based in Harbin City, the People's Republic of China.
IPO date
Dec 01, 2004
Employees
45
Domiciled in
CN
Incorporated in
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑06 | 2015‑06 | |
Income | |||||||||
Revenues | 112 41,689.89% | 267 -100.00% | |||||||
Cost of revenue | 111 | 2 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 220 | (1) | |||||||
NOPBT Margin | 0.20% | ||||||||
Operating Taxes | 3 | ||||||||
Tax Rate | |||||||||
NOPAT | 220 | (4) | |||||||
Net income | (409) 15.49% | (354) -127.41% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
Debt | |||||||||
Debt current | 5,154 | 6,760 | |||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | 5,107 | (38,030) | |||||||
Cash flow | |||||||||
Cash from operating activities | (42,272) | 2,116 | |||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | (39,652) | 2,799 | |||||||
Balance | |||||||||
Cash | 47 | 44,790 | |||||||
Long term investments | |||||||||
Excess cash | 42 | 44,790 | |||||||
Stockholders' equity | 38,588 | 42,281 | |||||||
Invested Capital | 44,222 | 7,149 | |||||||
ROIC | 0.00% | ||||||||
ROCE | 0.00% | ||||||||
EV | |||||||||
Common stock shares outstanding | 65,540 | 65,540 | |||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | 687 | 829 | |||||||
EV/EBITDA | |||||||||
Interest | 157 | ||||||||
Interest/NOPBT |